Stocks
Madrigal Pharmaceuticals, Inc.MDGL
NASDAQHealthcareBiotechnology$444.83+1.39%
Focused on metabolic liver disease, the company develops therapies targeting nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction–associated steatohepatitis (MASH). Its lead product, resmetirom, a thyroid hormone receptor‑beta agonist, received FDA approval in 2024,...
Market Cap: $10.1B52W Range: $265.00 – $615.00
Congressional Interest in Madrigal Pharmaceuticals, Inc. (MDGL)
1 member of Congress has disclosed 1 trade in Madrigal Pharmaceuticals, Inc. (MDGL), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading MDGL?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |